Compass Therapeutics Strengthens Leadership Team with Experienced Oncology Executives
Key Insights
Compass Therapeutics appointed Arjun Prasad (search) as Chief Commercial Officer and Cynthia Sirard (search) as Chief Medical Officer, both effective January 1, 2026.
Prasad brings extensive commercial experience including over 10 successful oncology launches, notably the blockbuster VORANIGO launch in 2024 and TIBSOVO for biliary tract cancer (search) patients.
Sirard contributes more than two decades of oncology drug development expertise, having guided multiple programs through clinical development, pivotal trials, and regulatory approval.
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, has appointed two seasoned executives to key leadership positions as it advances its immuno-oncology pipeline toward potential commercialization. The company announced that Arjun Prasad (search), MBA, MPH, has joined as Chief Commercial Officer and Cynthia Sirard (search), MD, as Chief Medical Officer, with both appointments effective January 1, 2026.
Strategic Leadership Additions
"We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience," said Thomas Schuetz (search), MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "Arjun's world-class expertise in oncology product launches and commercial strategy, specifically including a launch of a therapeutic indicated for the treatment of patients with biliary tract cancer (search) (BTC), will be so valuable as we advance tovecimig and our broader development portfolio."
The appointments represent a significant investment in commercial and clinical execution capabilities for the Boston-based company, which develops proprietary antibody-based therapeutics targeting the relationship between angiogenesis, the immune system, and tumor growth.
Commercial Leadership Experience
Prasad brings extensive commercial expertise from his most recent role as Chief Commercial Officer at Servier Pharmaceuticals, where he oversaw all commercial functions including Sales, Marketing, and Market Access. His career includes leadership positions at Agios Pharmaceuticals, where he led Global Oncology Marketing and Commercial Operations & Analytics, as well as roles of increasing seniority within Genentech's commercial organization.
Notably, Prasad has experience with over 10 successful oncology launches, including the recent blockbuster launch of VORANIGO in 2024. He also commercialized TIBSOVO for patients with biliary tract cancer (search) whose tumors have an actionable IDH1 (search) mutation in the second-line setting. Prasad holds a BA from Washington University in St. Louis and an MPH, MBA from Johns Hopkins University.
"I am honored to join Compass at such an exciting juncture," said Prasad. "I look forward to working with the team to advance a much-needed therapy, initially to patients with biliary tract cancer (search), but with much broader potential in a range of other oncology indications."
Clinical Development Expertise
Dr. Sirard joins Compass from Leap Therapeutics, where she served as Chief Medical Officer and spearheaded the development of first-in-class oncology agents. She also brings clinical development leadership experience from Sanofi and Genzyme. As a gastrointestinal-focused medical oncologist trained at Harvard Medical School's Beth Israel Deaconess Medical Center, Sirard is recognized as a global leader in advancing innovative immuno-oncology therapies.
Her expertise encompasses biomarker-driven strategies, global regulatory planning, and strategic partnerships with leading biopharma companies. Dr. Sirard has guided multiple programs through IND filings, clinical development, pivotal trials, and regulatory approval, bringing more than two decades of oncology drug development experience to Compass.
"Compass is approaching transformational milestones for tovecimig and its pipeline candidates, and it's very exciting to join at this inflection point," said Dr. Sirard. "Together, we will continue to advance the robust, science-driven pipeline to bring much needed innovation and therapeutic alternatives to patients facing life-threatening cancers."
Market Response and Investment Implications
The leadership appointments generated positive market response, with Compass Therapeutics shares rising 6.19% to $5.49 in pre-market trading on the Nasdaq following the announcement.
According to analysis from Simply Wall St, these hires bring deep experience in successful oncology drug launches and advancing immuno-oncology programs through pivotal trials and regulatory approvals, potentially strengthening Compass Therapeutics' execution capabilities. The appointments represent an early investment in launch and development execution, though near-term catalysts remain focused on clinical readouts, regulatory interactions, and potential partnering activities.
Company Pipeline Focus
Compass Therapeutics' scientific focus centers on the relationship between angiogenesis, the immune system, and tumor growth. The company's pipeline of novel product candidates targets multiple critical biological pathways required for an effective anti-tumor response, including modulation of the microvasculature via angiogenesis-targeted agents, induction of potent immune responses via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance.
The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Founded in 2014 and headquartered in Boston, Massachusetts, Compass continues to develop its immuno-oncology portfolio with the enhanced leadership team now in place.